免疫治疗给药时机对可切除非小细胞肺癌总生存的影响(iACORN研究):随机试验的系统综述与Meta分析
该系统综述与Meta分析纳入随机对照试验,评估新辅助、围手术期和术后免疫治疗对可切除非小细胞肺癌总生存的影响。共筛查865项研究,纳入分析4425例参与者。新辅助、围手术期和术后免疫治疗的死亡HR分别为0.57(95%CI 0.302-1.08)、0.67(95%CI 0.39-1.13)和0.94(95%CI 0.29-3.06)。作者认为新辅助和围手术期化疗-免疫治疗总生存相当,但新辅助疗程更短、费用更低,可考虑作为当前首选的多模式联合方案。
要点
- 新辅助、围手术期和术后免疫治疗的死亡HR分别为0.57、0.67和0.94,置信区间均跨1。
- 新辅助与围手术期化疗-免疫治疗的总生存结果相当。
- 作者认为新辅助化疗-免疫治疗因疗程更短、费用更低,可考虑作为当前首选多模式联合方案。
核心结论
- 在可切除非小细胞肺癌中,临床试验中辅助化疗-免疫治疗方案未带来统计学显著的总生存获益。
- 新辅助和围手术期化疗-免疫治疗的总生存结果相当,但鉴于新辅助疗程更短且费用更低,作者认为新辅助化疗-免疫治疗可考虑作为当前首选的多模式联合方案。
研究设计与样本
- 研究为随机对照试验的系统综述与Meta分析,检索MEDLINE、EMBASE、LILACS和Cochrane Library数据库自1980年1月1日起的文献。
- 排除病例报告、非随机研究、无免疫治疗组的研究以及结局数据报告不完整的研究(包括会议摘要)。
- 共筛查865项研究,去除非人类、非手术研究后评估58篇全文,这些研究共纳入4982例参与者,其中4425例纳入相应分析。
- 主要结局为总生存,采用随机效应Meta分析(DerSimonian and Laird法),研究注册于PROSPERO(CRD42023407825)。
主要发现
- 新辅助(术前)免疫治疗的死亡HR为0.57(95%CI 0.302-1.08)。
- 围手术期免疫治疗的死亡HR为0.67(95%CI 0.39-1.13)。
- 术后免疫治疗的死亡HR为0.94(95%CI 0.29-3.06)。
- 给药时机解释了真实效应量差异的100%(调节效应检验QM p=0.127),残余I²为0%(p=0.561)。
- 新辅助设置的不良事件OR为1.49(95%CI 0.64-3.47),围手术期设置的不良事件OR为1.34(95%CI 1.08-1.66)。
临床怎么用
- 作者认为,在可切除非小细胞肺癌中,新辅助化疗-免疫治疗可考虑作为当前首选的多模式联合方案。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We sought to investigate the relative impact of the timing of the administration of immunotherapy on survival in patients with resectable lung cancer. METHODS: We conducted a systematic review and meta-analysis of randomised controlled trials in this setting. We searched MEDLINE, EMBASE, LILACS and Cochrane Library databases from 1st January 1980 onwards. We excluded case reports; non-randomised studies; studies without an immunotherapy arm and if there was incomplete reporting on outcome data including conference abstracts. A standardised, pre-piloted form was used to extract data from the included studies for the assessment of study quality and for evidence synthesis. The primary outcome measure was overall survival which was assessed using random-effects meta-analyses (DerSimonian and Laird). The study was registered with PROSPERO (CRD42023407825). FINDINGS: We screened 865 studies and assessed 58 full text articles after removing non-human, non-surgical studies. These studies collectively enrolled 4982 participants and 4425 were included in the respective analyses. Hazard ratios (HRs) for death by timing of administration of immunotherapy, i.e., Neoadjuvant (pre-operative), peri-operative and post-operative were 0.57 (95 % CI 0.302-1.08), 0.67 (95 % CI 0.39-1.13) and 0.94 (95 % CI 0.29-3.06) respectively. The timing of administration accounted for 100 % of the difference in true effect size (test of moderators (QM p = 0.127), residual I2 0 %, p = 0.561). OR for adverse events was higher in the neoadjuvant setting compared to the peri-operative setting; 1.49 (0.64-3.47) and 1.34 (1.08-1.66) respectively. Bias assessment found the majority of studies to be low risk with respect to random sequencing, incomplete outcomes, and selective reporting. INTERPRETATION: In resectable non-small cell lung cancer, administration of adjuvant chemo-immunotherapy regimens in clinical trials did not lead to statistically significant survival benefits. Overall survival outcomes of neoadjuvant and peri-operative chemo-immunotherapy were comparable, but given the shorter duration and lower costs, neoadjuvant chemo-immunotherapy can be considered the current multimodality combination of choice.
引用
- Patel AJ, Hemead H, Law J, et al. Impact of the timing of immunotherapy administration on overall survival for resectable non-small cell lung cancer (iACORN study): A systematic review and meta-analysis of randomised trials. Eur J Cancer. 2024. PMID: 39551030. doi:10.1016/j.ejca.2024.115118
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。